Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Termination reflected clinical disappointment rather than strategic realignment — semorinemab missed in TAURIEL (2020) and crenezumab failed Phase 2…
Combined crenezumab and semorinemab deals were valued at over $700M; their return ends a multi-program collaboration that had been one of Roche's largest…
Semorinemab demonstrated a 43.6% slowing of decline on ADAS-Cog11 in LAURIET but no benefit on functional outcomes — a mixed signal that proved insufficient to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Genentech (Roche) and AC Immune exclusive worldwide license/research collaboration for anti-tau antibodies in Alzheimer's. Undisclosed upfront plus up to CHF 400M (~$418M) in research/dev/commercial milestones. Built on prior crenezumab (anti-amyloid) deal from 2006.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / AC Immune SA (this deal) | 2012 | $418M | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2012 deals · Roche Holding AG deals · Neurology deals